© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 16, 1391-1397,
August 18, 1999
© 1999 Oxford University Press
REPORTS |
Loss of Heterozygosity at D14S62 and Metastatic Potential of Breast Cancer
Affiliations of authors: P. O'Connell, K. Fischbach, S. K. Mohsin, D. C. Allred (Department of Pathology), S. Hilsenbeck, S. A. W. Fuqua, G. M. Clark, C. K. Osborne (Division of Oncology, Department of Medicine), The University of Texas Health Science Center at San Antonio.
Correspondence to present address: Peter O'Connell, Ph.D., Baylor College of Medicine, Baylor Breast Center, One Baylor Plaza, MS600, Houston, TX 77030.
BACKGROUND: In breast cancer progression, the prevalence of damage at specific genetic loci often increases with the stage of the lesion (i.e., from noninvasive to invasive to metastatic). By use of genetic markers and analysis of allelic imbalances (loss of heterozygosity [LOH]) to compare DNA samples from paired normal and breast tumor tissues, we examined whether specific genetic changes in primary breast cancers can serve as biomarkers of metastatic potential. METHODS: DNA samples from 76 patients with primary breast cancer (42 with axillary lymph node-negative disease and 34 with axillary lymph node-positive disease) were genotyped with four genetic markers spanning chromosome 14q31-q32. The intensity ratios of the two genetic alleles in normal-tumor DNA pairs were examined in genetically informative individuals. LOH was scored when the tumor allele intensity ratio (tumor allele 1/tumor allele 2) divided by the normal allele intensity ratio (normal allele 1/normal allele 2) was either less than 0.71 (tumor allele 1 LOH) or greater than 1.4 (tumor allele 2 LOH). RESULTS/CONCLUSIONS: Contrary to our expectations, we found statistically significantly more LOH events at markers D14S62 (two-sided P = .001) and D14S51 (two-sided P = .02) in primary breast cancers from patients with lymph node-negative disease versus lymph node-positive disease, suggesting the presence of a gene in this region that affects metastatic potential. Analysis of small interstitial or terminal deletions in the tumors of six especially informative patients with lymph node-negative disease places the putative metastasis-related gene in a 1490-kilobase region near D14S62. IMPLICATIONS: LOH in the D14S62 region may impede the process of metastasis. Therefore, the D14S62 region LOH profile may have prognostic implications, and the isolation of the metastasis-related gene(s) in this region may lead to better diagnosis and treatment of breast cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. K. L. Cheung, H. L. Lung, J. M. Y. Ko, Y. Cheng, E. J. Stanbridge, E. R. Zabarovsky, J. M. Nicholls, D. Chua, S. W. Tsao, X.-Y. Guan, et al. Chromosome 14 transfer and functional studies identify a candidate tumor suppressor gene, Mirror image polydactyly 1, in nasopharyngeal carcinoma PNAS, August 25, 2009; 106(34): 14478 - 14483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kawakami, T. Chano, K. Minami, H. Okabe, Y. Okada, and K. Okamoto Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma Hum. Mol. Genet., March 15, 2006; 15(6): 821 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Taback, A. E. Giuliano, N. M. Hansen, F. R. Singer, S. Shu, and D. S. B. Hoon Detection of Tumor-Specific Genetic Alterations in Bone Marrow from Early-Stage Breast Cancer Patients Cancer Res., April 15, 2003; 63(8): 1884 - 1887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Kamnasaran and D W Cox Current status of human chromosome 14 J. Med. Genet., February 1, 2002; 39(2): 81 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Martin, K. Fischbach, C. K. Osborne, S. K. Mohsin, D. C. Allred, and P. O’Connell Loss of Heterozygosity Events Impeding Breast Cancer Metastasis Contain the MTA1 Gene Cancer Res., May 1, 2001; 61(9): 3578 - 3580. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Takahashi, R. Kawanishi-Tabata, A. Haba, M. Tabata, Y. Haruta, H. Tsai, and B. K. Seon Association of Serum Endoglin with Metastasis in Patients with Colorectal, Breast, and Other Solid Tumors, and SuppressiveEffect of Chemotherapy on the Serum Endoglin Clin. Cancer Res., March 1, 2001; 7(3): 524 - 532. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. W. Gray and C. Collins Genome changes and gene expression in human solid tumors Carcinogenesis, March 1, 2000; 21(3): 443 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Welch and C. W. Rinker-Schaeffer What Defines a Useful Marker of Metastasis in Human Cancer? J Natl Cancer Inst, August 18, 1999; 91(16): 1351 - 1353. [Full Text] [PDF]
|
|